Skip to main navigation Skip to search Skip to main content

Plasma enhance drug sensitivity to bortezomib by inhibition of cyp1a1 in myeloma cells

  • Xi'an Jiaotong University

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Background: Drug resistance is one of the major problems encountered in clinical therapy of multiple myeloma treatment. Combination treatment with several drugs may increase the sensitivity and overcome drug resistance. Methods: Here, we combined chemotherapy with a newly developed technology, cold atmospheric plasma, to enhance drug sensitivity. Results: We found that plasma treatment had a synergistic anti-cancer effect with a first line drug (bortezomib). Based on our previous study, we further found that plasma treatment could inhibit Notch pathway and down-regulate cyp1a1 expression and enzyme activity, which contributing to the enhanced drug sensitivity to bortezomib after combination of bortezomib with gas plasma. Conclusions: Our results showed a new strategy to overcome drug resistance by combination of traditional chemotherapy with cold atmospheric plasma.

Original languageEnglish
Pages (from-to)2841-2847
Number of pages7
JournalTranslational Cancer Research
Volume8
Issue number8
DOIs
StatePublished - 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Cold atmospheric plasma
  • Cyp1a1
  • Drug resistance
  • Multiple myeloma (MM)
  • Notch

Fingerprint

Dive into the research topics of 'Plasma enhance drug sensitivity to bortezomib by inhibition of cyp1a1 in myeloma cells'. Together they form a unique fingerprint.

Cite this